Thrilled to announce our latest investment into Wayland Additive as part of a £4.2m funding round. Wayland is a Huddersfield-based company providing electron beam, 3D printing technology using Calibur3 metal additive manufacturing (AM) machines and will use the funding to improve in-house production capability and increase their global customer base. Wayland Additive, the electron beam
We are delighted to announce the launch of our Imperial College Enterprise Fund (ICEF) III. The Fund is managed by Parkwalk in conjunction with Imperial Enterprise. The Fund invests in early-stage hard science and disruptive technology companies, linked to Imperial College, one of the world’s top 10 ranked universities. Tuesday 16 January 2024, London: Parkwalk
In general, 2023 was a challenging year for venture capital, with continuing macro-economic uncertainties and a volatile geopolitical backdrop, as well as the interest rate cycle adversely impacting the sector. There were, however, some positives for the UK-specific sector last year, with the EIS and VCT Sunset clause being extended to 2035, which is good
After fifteen years at the helm of Parkwalk, Alastair Kilgour has decided to step back from being Chief Investment Officer with effect from the end of December 2023. He will, of course, remain a Founder of Parkwalk and will spend several months handing over the role and responsibilities to John Pearson, who will be taking
Parkwalk are thrilled to have won ‘Best EIS Investment Manager’ at the Growth Investor Awards 2023, for the second year running. The judges recognised our returns to our investors and our unique strategy investing into cutting-edge technologies spinning out of top UK universities and research institutions. Now in their 9th year, the Growth Investor Awards
Along with 100 experts from Graphcore, Arm, Google and Stripe, we are proud to support the Founders at the University of Cambridge, with Cambridge Enterprise, aiding the next generation of start-ups. This new initiative is the first pre-seed accelerator for the University and as part of the first 12-week programme, up to 10 early-stage companies
MeVitae has developed software to streamline recruitment processes, using data-driven technology to attract, screen and retain top talent whilst building diverse and productive teams fairly. The software aims to eliminate 15 bias parameters using its suite of Artificial Intelligence-based solutions.
We are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund III, an HMRC-approved EIS Fund. As featured in Investment Week, the third Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities and research institutions, mirroring the investment strategy of our Opportunities EIS Fund. Parkwalk Advisors, the
We are delighted to announce that our University of Oxford Innovation Fund VI is now closed, surpassing its target and raising £3m. As featured in an article by UKTN, the Fund is run in conjunction with Oxford University Innovation, backing cutting-edge technology and science spin-outs from the University of Oxford. Oxford University Innovation and Parkwalk
Parkwalk is pleased to announce that portfolio company, Mogrify, have extended their Series A financing to $46m USD. The University of Cambridge and University of Bristol spinout is enabling the next generation of gene sequencing and gene-regulatory data to help transform the lives of patients living with degenerative diseases. This funding round aims to support
Parkwalk have launched our annual ‘Equity Investments into Spinouts’ 2023 report, in conjunction with Beauhurst. The report findings also feature in the Financial Times, “Investment in UK university spinouts falls after decade of growth“ article, where Moray Wright, CEO, Parkwalk, calls for further action to channel more UK investment into high-potential spinouts. Download the ‘Equity
Parkwalk are delighted to announce the acquisition of our portfolio company PetMedix, generating a positive return for our EIS investors. PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced that it has been acquired by the world’s leading animal health company. In addition to successful research collaborations, PetMedix’s proprietary drug development activities have
We are delighted to announce our latest investment into Phasecraft as part of a £13m Series A Funding Round. The University College London spin-out designs quantum software for quantum information processors encompassing both near-term intermediate-scale devices and universal fault-tolerant computers. This latest funding round will help the company to develop Phasecraft’s quantum algorithms to the point of practical
Parkwalk is thrilled to announce our latest investment into Entia as part of a $20m series A funding round to launch the world’s most comprehensive monitoring solution for patients undergoing cancer therapy. Healthtech company Entia has closed a successful $20m Series A financing round. The round was led by BGF and Parkwalk plus other existing investors, with
Concr is a value-driven techbio company, spun out of the University of Cambridge, applying statistical learning and advanced modelling adopted from astrophysics to aid in the precision treatment of cancer patients. Concr’s online platform allows the storage, management and analysis of data generating actionable insights for cost-effective drug development and patient treatment.
We are delighted to announce the launch of our University of Oxford Innovation Fund (UOIF) VI. The fund is managed by Parkwalk, in conjunction with the University of Oxford’s Technology Transfer Office, Oxford University Innovation. The Fund invests in early-stage hard science and deep-tech companies, spun-out of the University of Oxford, the UK’s largest research-based
On Wednesday 7th June 2023, we held our annual Portfolio Showcase at the Royal Society of Chemistry, showcasing innovative companies from our portfolio. The portfolio showcase brought together 20 of our ground-breaking EIS investment companies from the UK’s top universities, including the Golden Triangle; Cambridge, Oxford and London. The evening was a great success, with
Parkwalk is delighted to announce Oxbotica’s rebranding to Oxa, marking the next stage in the company’s growth as it prepares to scale in North America and Europe. Oxa has developed autonomous vehicle software that operates anywhere without dependence on external systems such as GPS and third-party maps. Oxa’s journey has been exciting to watch and
Parkwalk announces our recent funding round into new portfolio company AccelerComm. The University of Southampton spin-out has developed patented communication algorithms for 5G, doubling network capacity whilst halving power consumption and slashing latency. The company’s patent-protected solutions offer a complete physical layer of IP solutions enabling optimal performance for 5G radio access networks. This latest
Parkwalk is delighted to announce that, in a first for the graphene electronics industry, leading integrated device manufacturer Paragraf is acquiring graphene biosensor market pioneer Cardea Bio. This acquisition will accelerate the mass production of a new generation of devices that will deliver real-time analysis in point-of-need tests in the agritech, healthcare and environmental monitoring
